ROCKVILLE - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 11 June 2024, a total of 325,608 options in respect of common stock in the Company, and 170,936 restricted stock units ('RSU's) were granted to PDMRs who are non-executive directors of the Company.

These Options Grants and RSUs were made pursuant to the Company's Equity Grant Policy for non-executive directors.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

Contact:

David Deuchler

Tel: +1 415-937-5400

Email: ir@maxcyte.com

Chris Welsh

Tel: +44 (0)203 709 5700

Email: maxcyte@consilium-comms.com

(C) 2024 Electronic News Publishing, source ENP Newswire